Literature DB >> 32339541

Anticancer mechanisms of metformin: A review of the current evidence.

Bin Zhao1, Jie Luo1, Tongyao Yu1, Liangfu Zhou1, Huanhuan Lv1, Peng Shang2.   

Abstract

Metformin, a US Food and Drug Administration-approved "star" drug used for diabetes mellitus type 2, has become a topic of increasing interest to researchers due to its anti-neoplastic effects. Growing evidence has demonstrated that metformin may be a promising chemotherapeutic agent, and several clinical trials of metformin use in cancer treatment are ongoing. However, the anti-neoplastic effects of metformin and its underlying mechanisms have not been fully elucidated. In this review, we present the newest findings on the anticancer activities of metformin, and highlight its diverse anticancer mechanisms. Several clinical trials, as well as the limitations of the current evidence are also demonstrated. This review explores the crucial roles of metformin and provides supporting evidence for the repurposing of metformin as a treatment of cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Autophagy; Epigenetic modification; Immunoregulation; Metformin

Mesh:

Substances:

Year:  2020        PMID: 32339541     DOI: 10.1016/j.lfs.2020.117717

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  23 in total

1.  Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta-Analysis.

Authors:  Mingchuan Guo; Xiaofei Shang; Duanying Guo
Journal:  Int J Clin Pract       Date:  2022-02-28       Impact factor: 3.149

2.  Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1.

Authors:  Xiaowen Hu; Mengsiyu Li; Chunxue Zhang; Shuguang Pang
Journal:  Int J Endocrinol       Date:  2021-02-15       Impact factor: 3.257

3.  Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis.

Authors:  Yung-An Tsou; Wei-Chao Chang; Chia-Der Lin; Ro-Lin Chang; Ming-Hsui Tsai; Liang-Chun Shih; Theresa Staniczek; Tsu-Fang Wu; Hui-Ying Hsu; Wen-Dien Chang; Chih-Ho Lai; Chuan-Mu Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-26

4.  Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.

Authors:  Aroa Baragaño Raneros; Ramon M Rodriguez; Aida Bernardo Flórez; Pilar Palomo; Enrique Colado; Alfredo Minguela; Beatriz Suárez Álvarez; Carlos López-Larrea
Journal:  Oncoimmunology       Date:  2021-03-25       Impact factor: 8.110

5.  Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.

Authors:  Daniel L Smith; Rachael M Orlandella; David B Allison; Lyse A Norian
Journal:  Geroscience       Date:  2020-10-02       Impact factor: 7.713

6.  Incorporation of Sulfonamide Moiety into Biguanide Scaffold Results in Apoptosis Induction and Cell Cycle Arrest in MCF-7 Breast Cancer Cells.

Authors:  Magdalena Markowicz-Piasecka; Karol Sadowski; Johanna Huttunen; Joanna Sikora; Kristiina M Huttunen
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 7.  Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio.

Authors:  Marike W van Gisbergen; Emma Zwilling; Ludwig J Dubois
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

8.  Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC.

Authors:  Shuang Liu; Erik V Polsdofer; Lukun Zhou; Sanbao Ruan; Hui Lyu; Defu Hou; Hao Liu; Ann D Thor; Zhimin He; Bolin Liu
Journal:  Mol Ther Oncolytics       Date:  2021-04-29       Impact factor: 7.200

9.  Metformin alters therapeutic effects in the BALB/c tumor therapy model.

Authors:  Felix B Meyer; Sophie Goebel; Sonja B Spangel; Christiane Leovsky; Doerte Hoelzer; René Thierbach
Journal:  BMC Cancer       Date:  2021-05-28       Impact factor: 4.430

10.  Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells.

Authors:  Madhuri Shende Warkad; Chea-Ha Kim; Beom-Goo Kang; Soo-Hyun Park; Jun-Sub Jung; Jing-Hui Feng; Gozde Inci; Sung-Chan Kim; Hong-Won Suh; Soon Sung Lim; Jae-Yong Lee
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.